10 Stocks Dominating Today's Market Surge: ImmunityBio, Alkermes, and More
On the previous day, SoundHound AI (NASDAQ:SOUN) fell to a 52-week low of $5.83.
Apellis Pharmaceuticals Inc. (APLS)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 12,222,222 | $491,699,991 | 4.84% | |
| 2. | Pentwater Capital Management Matthew Halbower | 5,250,000 | $211,207,500 | 1.1% | |
| 3. | Deep Track Capital David Kroin | 4,532,374 | $182,337,406 | -42% | 2.98% |
| 4. | Point72 Asset Management Steve Cohen | 4,183,918 | $168,319,021 | +601% | 0.22% |
| 5. | HBK Investments David Costen Haley | 3,550,000 | $142,816,500 | 1.45% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 250,000 | $10,000,000.00 | 12,806,342 | 2021-11-18 | Filing | |
| $31.81 | 5,000 | $159,034.00 | 5,000 | 2020-05-08 | Filing | |
| $37.00 | 540,540 | $19,999,980.00 | 12,556,342 | 2020-01-13 | Filing | |
| $29.71 | 11,699 | $347,629.94 | 11,699 | 2019-08-29 | Filing | |
| $17.00 | 441,176 | $7,499,992.00 | 12,015,802 | 2019-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.15 | 368 | $8,152.56 | 114,591 | 2026-02-11 | Filing | |
| $21.77 | 2,797 | $60,877.82 | 86,527 | 2026-01-22 | Filing | |
| $21.77 | 2,064 | $44,923.79 | 49,805 | 2026-01-22 | Filing | |
| $21.77 | 3,371 | $73,371.16 | 78,353 | 2026-01-22 | Filing | |
| $21.77 | 5,928 | $129,025.29 | 1,151,382 | 2026-01-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,536,964 | $544,592,062 | 0.01% | |
| 2. | 10,042,399 | $404,005,720 | 0.02% | |
| 3. | 6,844,990 | $275,373,948 | 0.01% | |
| 4. | 6,206,681 | $249,694,778 | 0.04% | |
| 5. | 5,404,559 | $217,425,409 | 0.01% |
News See All
Cantor Fitzgerald Cuts PT on Apellis Pharmaceuticals (APLS) to $31 From $35 - Here's Why
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the best high growth healthcare stocks to buy now. Cantor Fitzgerald cut the price target on Apellis Pharmaceuticals, Inc.
11 High Growth Healthcare Stocks to Buy Now
On March 26, Stephanie Link, Hightower chief investment strategist, appeared on CNBC's ‘Squawk Box’ to talk about the latest market trends, where investors can find opportunities, and the effects ...
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS)
On March 5, Anupam Rama from JPMorgan increased the price target on Apellis Pharmaceuticals Inc. (NASDAQ:APLS) from $36 to $37.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript February 24, 2026Apellis Pharmaceuticals, Inc. misses on earnings expectations.
BofA Upgrades Apellis (APLS) to Buy Citing Rapid Empaveli Adoption and Underappreciated Kidney Disease Market Potential
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best high short interest stocks with biggest upside potential.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy
Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now.
12 Best Upside Stocks to Buy Now
On November 14, Alli McCartney, UBS Private Wealth Management managing director, joined 'Squawk Box' on CNBC to discuss the latest market trends and what to make of the recent volatility.
Hedge Fund Resource Center